Studies showing that hormone replacement therapy can raise the risk of heart disease, cancer and blood clots have knocked U.S. prescriptions for the drugs back to where they were nine years ago, according to a report in this week's issue of the Journal of the American Medical Association.
This suggests that doctors "may rapidly abandon well-established therapies when studies demonstrate harm" and that "patients also played a major role" in the reversal, Stanford University School of Medicine researchers noted.
The authors found that the number of hormone therapy prescriptions rose to 90 million in 1999 from 58 million in 1995 and remained stable through June 2002. Estrogen/progestin combinations, primarily Wyeth's Prempro, accounted for most of the growth.
Study findings released starting in July 2002 triggered an avalanche of bad news about the therapy, and a sharp drop in prescriptions followed.
If prescription rates seen through July 2003 continue, the report said, there were probably 57 million written last year, close to the rate in 1995.
The U.S. Food and Drug Administration recommends that post-menopausal women who take hormone therapy for hot flashes or vaginal dryness use the lowest possible dose for the shortest possible time.
SOURCE: Journal of the American Medical Association, January 7, 2003.
Ultimi Articoli
Domenico Formichetti porta CASA BLASTER alla Milano Design Week 2026
Benji & Fede tornano il 24 aprile con Oh, Maria! — a ottobre il debutto nei teatri italiani
Polignano a Mare — Si chiude la tre giorni dedicata a Domenico Modugno, tra bande, cinema e memoria condivisa
Triennale Milano apre mostre e incontri per la Milano Design Week 2026
Milano — “Gente di facili costumi” al Manzoni, ritmo vivo e dialoghi che tengono la scena
Triennale Milano apre la Design Week con mostre, incontri e laboratori
GENTE DI FACILI COSTUMI al Teatro Manzoni di Milano
Milano: George Foreman, la sua storia arriva in libreria con DIO AL MIO ANGOLO
Arisa torna con Foto Mosse — il nuovo album esce il 17 aprile